RxDoctor Payments Data

Supriya Rao, MD

Internal Medicine · Lowell, MANPI 1205098886

Payments from drug & device makers

$27,709in general payments, 2019–2025

Across 163 payments — averaging $169.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$17K
  • Lilly USA, LLC$6K
  • Celltrion USA Inc.$1K
  • AbbVie$593
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$463
  • Gilead$343
  • plus $2K from 19 others

What the payments were for

  • Speaking & faculty fees$24,20687%
  • Food & beverage$3,48113%
  • Education$210%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$27,709 in reported general payments places this provider in the 95th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$225,883
Medicare patients
571
Services billed
2,981

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab18$500,254
MounjaroTirzepatide77$87,775
XifaxanRifaximin20$73,531
LinzessLinaclotide66$47,326
OzempicSemaglutide45$46,351
WegovySemaglutide20$30,214
Dexlansoprazole DrDexlansoprazole36$16,342
Mesalamine43$12,987
SutabSod Sulf/Pot Chloride/Mag Sulf64$10,636
TrulancePlecanatide16$9,028
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates35$2,050
Omeprazole110$1,959
Dicyclomine Hcl32$1,187
Pantoprazole Sodium57$1,045
Sucralfate15$423

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$112$500,25418 claims
Lilly USA, LLCMounjaro$6,129$87,77577 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance$463$82,55936 claims
Novo NordiskOzempic, Wegovy$75$76,56565 claims
AbbVieLinzess$593$47,32666 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,983 internal medicine providers in Massachusetts.

Other internal medicine in Lowell

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →